Microcell-mediated chromosome transfer identifies EPB41L3 as a functional suppressor of epithelial ovarian cancers

Neoplasia

Volumn 12, Issue 7, 2010, Pages 579-589

  Dafou, Dimitra ^a   Grun, Barbara ^a   Sinclair, John ^a   Lawrenson, Kate ^a   Benjamin, Elizabeth C ^b   Hogdall, Estrid ^c   Kruger Kjaer, Susanne ^c   Christensen, Lise ^d   Sowter, Heidi M ^e   Al Attar, Ahmed ^f   Edmondson, Richard ^g   Darby, Stephen ^g   Berchuck, Andrew ^h   Laird, Peter W ⁱ   Pearce, C L ^j   Ramus, Susan J ^a   Jacobs, Ian J ^a   Gayther, Simon A ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c INSTITUTE OF CANCER EPIDEMIOLOGY   (Denmark)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

^e UNIVERSITY OF DERBY   (United Kingdom)

^f UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^g NEWCASTLE UNIVERSITY   (United Kingdom)

^h DUKE CANCER INSTITUTE   (United States)

ⁱ UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^j UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROCYTE MEMBRANE PROTIN BAND 4.1 LIKE 3; MEMBRANE PROTEIN; UNCLASSIFIED DRUG; ACTIN BINDING PROTEIN; EPB41L3 PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

APOPTOSIS; ARTICLE; CHROMOSOME 18; CONTROLLED STUDY; DNA METHYLATION; EPITHELIUM CELL; GENE FUNCTION; GENE INACTIVATION; GENE MAPPING; GENE OVEREXPRESSION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; METHYLATION; OVARY CANCER; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SCANNING ELECTRON MICROSCOPY; TRANSMISSION ELECTRON MICROSCOPY; CELL CULTURE; CULTURE TECHNIQUE; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE TRANSFER; GENETIC ASSOCIATION; GENETICS; HYBRID CELL; METABOLISM; MICROARRAY ANALYSIS; MULTICELLULAR SPHEROID; NEOPLASM; OVARY TUMOR; PATHOLOGY; PHYSIOLOGY; TUMOR SUPPRESSOR GENE;

APOPTOSIS; CELL CULTURE TECHNIQUES; CELLS, CULTURED; CHROMOSOMES, HUMAN, PAIR 18; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE TRANSFER TECHNIQUES; GENES, TUMOR SUPPRESSOR; GENETIC ASSOCIATION STUDIES; HUMANS; HYBRID CELLS; MEMBRANE PROTEINS; MICROARRAY ANALYSIS; MICROFILAMENT PROTEINS; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; SPHEROIDS, CELLULAR; TUMOR SUPPRESSOR PROTEINS;

EID: 77954977614     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.10340     Document Type: Article

References (42)

1. Stanbridge EJ and Wilkinson J (1978). Analysis of malignancy in human cells: malignant and transformed plienotypes are under separate genetic control. Proc Natl Acad Sci USA 75(3), 1466-1469.
2. Stanbridge EJ, Flandermeyer RR, Daniels DW, and Nelson-Rees WA (1981). Specific chromosome loss associated with the expression of tumorigenicity in human cell hybrids. Somatic Cell Genet 7(6), 699-712.
3. Saxon PJ, Leipzig ES, Srivatsan GV, Sameshima JH, and Stanbridge EJ (1985). Selective transfer of individual human chromosomes to recipient cells. Mol Cell Biol 5(1), 140-146.
4. Eklund LK, Islam K, Söderkvist P, and Islam MQ (2001). Regional mapping of suppressor loci for anchorage independence and tumorigenicity on human chromosome 9. Cancer Genet Cytogenet 130(2), 118-126.
5. Fukuhara H, Maruyama T, Nomura S, Oshimura M, Kitamura T, Sekiya T, and Murakami Y (2001). Functional evidence for the presence of tumor suppressor gene on chromosome 10pl5 in human prostate cancers. Oncogene 20(3), 314-319.
6. Cheng Y, Chakrabarti R, Garcia-Barcelo M, Ha TJ, Srivatsan ES, Stanbridge EJ, and Lung ML (2002). Mapping of nasopharyngeal carcinoma tumor-suppressive activity to a 1.8-megabase region of chromosome band 1 lql3. Genes Chromosomes Cancer 34(1), 97-103.
7. Flanagan JM, Healey S, Young J, Whitehall V, Trott DA, Newbold RF, and Chenevix-Trench G (2004). Mapping of a candidate colorectal cancer tumor-suppressor gene to a 900-kilobase region on the short arm of chromosome 8. Genes Chromosomes Cancer 40(3), 247-260.
8. Gagnon A, Ripeau JS, Zvieriev V, and Chevrette M (2006). Chromosome 18 suppresses tumorigenic properties of human prostate cancer cells. Genes Chromosomes Cancer 45(3), 220-230.
9. Seitz S, Frege R, Jacobsen A, Weimer J, Arnold W, von Haefen C, Niederacher D, Schmutzler R, Arnold N, and Scherneck S (2005). A network of cynically and functionally relevant genes is involved in the reversion of the tumorigenic phenotype of MDA-MB-231 breast cancer cells after transfer ofhuman chromosome 8. Oncogene 24(5), 869-879.
10. Ko JM, Chan PL, Yau WL, Chan HK, Chan KC, Yu ZY, Kwong FM, Miller LD, Liu ET, Yang LC, et al. (2008). Monochromosome transfer and microarray analysis identify a critical tumor-suppressive region mapping to chromosome 13ql4 and THSD1 in esophageal carcinoma. Mol Cancer Res 6(4), 592-603.
11. Lung HL, Lo CC, Wong CC, Cheung AK, Cheong KF, Wong N, Kwong FM, Chan KC, Law EW, Tsao SW. et al. (2008). Characterization of a novel epigenetically-silenced, growth-suppressive gene, ADAMTS9, and its association with lymph node metastases in nasopharyngeal carcinoma Int J Cancer 123(2), 401-408.
12. Wan M, SunT, VyasR, Zheng J, Granada E, and DubeauL (1999). Suppression of tumorigenicity in human ovarian cancer cell lines is controlled by a 2 cM fragment in chromosomal region 6q24-q25. Oncogene 18(8), 1545-1551.
13. Kruzelock R P, Cuevas BD, Wiener JR, XuFJ, Yu Y, Cabeza-Arvelaiz Y, Pershouse M, Lovell MM, Killary AM, Mills GB. et al. (2000). Functional evidence for an ovarian cancer tumor suppressor gene on chromosome 22 by microcell-mediated chromosome transfer. Oncogene 19(54), 6277-6285.
14. Cao Q, Abeysinghe H, Chow O, Xu J, Kaung H, Fong C, Keng P, Insel RA, Lee WM, Barrett JC, et al. (2001). Suppression of tumorigenicity in human ovarian carcinoma cell line SKOV-3 by microcell-mediated transfer of chromosome 11. Cancer Genet Cytogenet 129(2), 131-137.
15. Stronach EA, Sellar GC, Blenkiron C, Rabiasz GJ, Taylor KJ, Miller EP, Massie CE, Al-Nafussi A, Smyth JF, Porteous DJ. et al. (2003). Identification of clinically relevant genes on chromosome 11 in a functional model of ovarian cancer tumor suppression. Cancer Res 63(24), 8648-8655.
16. Cannistra SA (2004). Cancer of the ovary. N Engl J Med 351(24), 2519-2529.
17. Ramus SJ, Pharoah PD, Harrington P, Pye C, Werness B, Bobrow L, Ayhan A, Wells D, Fishman A, Gore M. et al. (2003). BRCA1/2 mutation status influences somatic genetic progression in inherited and sporadic epithelial ovarian cancer cases. Cancer Res 63(2), 417-423.
18. Dafou D, Ramus SJ, Choi K, Grun B, Trott DA, Newbold RF, Jacobs IJ, Jones C, and Gayther SA (2009). Chromosomes 6 and 18 induce neoplastic suppression in epithelial ovarian cancer cells. Int J Cancer 124, 1037-1044.
19. Cuthbert AP, Trott DA, Ekong RM, Jezzard S, England NL, Themis M, Todd CM, and Newbold RF (1995). Construction and characterization of a highly stable human: rodent monochromosomal hybrid panel for genetic complementation and genome mapping studies. Cytogenet Cell Genet 71(1), 68-76.
20. Li NF, Broad S, Lu YJ, Yang JS, Watson R, Hagemann T, Wilbanks G, Jacobs I, Balkwill F Dafou D. et al. (2007). Human ovarian surface epithelial cells immortalized with hTERT maintain functional pRb and p53 expression. Cell Prolif 40(5), 780-794.
21. Neuvial P, Hupe P, Brito I, Liva S, Manie E, Brennetot C, Radvanyi F, Aurias A, and Barillot E (2006). Spatial normalization of array-CGH data BMC Bioinformatics 7, 264-266.
22. Benjamini Y and Yekutieli D (2005). Quantitative trait loci analysis using the false discovery rate. Genetics 171(2), 783-790.
23. Hogdall EV Christensen L, Kjaer SK, Blaakaer J, Jarle Christensen I, Gayther S, Jacobs IJ, and Hogdall CK. (2008). Protein expression levels of carcinoembryonic antigen (CEA) in Danish ovarian cancer patients. Pathology 40(5), 487-492.
24. Kelm JM, Timmins NE, Brown CJ, Fussenegger M, and Nielsen LK (2003). Method for generation of homogeneous multicellular tumor spheroids applicable to a wide variety of cell types. Biotechnol Bioeng 83(2), 173-180.
25. Grun B, Benjamin E, Sinclair J, Timms JF, Jacobs IJ, Gayther SA, and Dafou D (2009). A description of a three dimensional model of ovarian and endometrial cancer. Cell Prolif42, 219-228.
26. Lawrenson K, Benjamin E, Turmaine M, Jacobs I, Gayther S, and Dafou D (2009). In vitro three-dimensional modelling of human ovarian surface epithelial cells. Cell Prolif 42, 385-393.
27. Quaye L, Dafou D, Ramus SJ, Song H, Gentry-Maharaj A, Notaridou M, Hogdall E, Kjaer SK, Christensen L, Hogdall C. et al. (2009). Functional complementation studies identify candidate genes and common genetic variants associated with ovarian cancer survival. Hum Mol Genet 18, 1869-1878.
28. Coelho D, Suormala T, Stucki M, Lerner-Ellis JP, Rosenblatt DS, Newbold RF, Baumgartner MR, and Fowler B (2008). Gene identification for the cblD defect of vitamin B12 metabolism. N Engl J Med 358(14), 1454-1464.
29. Rutsch F, Gailus S, Miousse IR, Suormala T, Sagne C, Toliat MR, Niirnberg G, Wittkampf T, BuersI, Sharif! A. etal. (2009). Identification of a putative lysosomal cobalamin exporter altered in the cblF defect of vitamin B(12) metabolism. Nat Genet41(2), 234-239.
30. Kobel M, Kalloger SE, Boyd N, McKinney S, Mehl E, Palmer C, Leung S, Bowen NJ, Ionescu DN, Rajput A. et al. (2008). Critical molecular abnormalities in high-grade serous carcinoma of the ovary. Expert Rev Mol Med 10, e22.
31. Kikuchi S, Yamada D, Fukami T, Masuda M, Sakurai-Yageta M, Williams YN, Maruyama T, Asamura H, Matsuno Y, Onizuka M. et al. (2005). Promoter meth-ylation of DAL-1/4.1B predicts poor prognosis in non-small cell lung cancer. Clin Cancer Res 11(8), 2954-2961.
32. Yamada D, Kikuchi S, Williams YN, Sakurai-Yageta M, Masuda M, Maruyama T, Tomita K, Gutmann DH, Kakizoe T, Kitamura T. et al. (2006). Promoter hypermethylation of the potential tumor suppressor DAL-114. IB gene in renal clear cell carcinoma. Int J Cancer 118(4), 916-923.
33. Tsujiuchi T, Masaoka T, Sugata E, Onishi M, Fujii H, Shimizu K, and Honoki K (2007). Hypermethylation of the Dal-1 gene in lung adenocarcinomas induced by TV-nitrosobis(2-hydroxypropyl)amine in rats. Mol Carcinog 46(10), 819-823.
34. Schulz WA, Alexa A, Jung V, Hader C, Hoffmann MJ, Yamanaka M, Fritzsche S, Wlazlinski A, Miiller M, Lengauer T. et al. (2007). Factor interaction analysis for chromosome 8 and DNA methylation alterations highlights innate immune response suppression and cytoskeletal changes in prostate cancer. Mol Cancer 6, 14.
35. Martinez-Glez V, Bello MJ, Franco-Hernandez C, De Campos JM, Isla A, Vaquero J, and Rey JA (2005). Mutational analysis of the DAL-1/4.1B tumour-suppressor gene locus in meningiomas. Int J Mol Med 16(4), 771-774.
36. Yi C, McCarty JH, Troutman SA, Eckman MS, Bronson RT, and Kissil JL (2005). Loss of the putative tumor suppressor band 4.1BIDall gene is dispensable for normal development and does not predispose to cancer. Mol Cell Biol 25(22), 10052-10059.
37. Wong SY, Haack H, Kissil JL, Barry M, Bronson RT, Shen SS, Whittaker CA, Crowley D, and Hynes RO (2007). Protein 4.IB suppresses prostate cancer progression and metastasis. Proc Natl Acad Sci USA 104(31), 12784-12789.
38. Charboneau AL, Singh V, Yu T, and Newsham IF (2002). Suppression of growth and increased cellular attachment after expression of DAL-1 in MCF-7 breast cancer cells. Int J Cancer 100(2), 181-188.
39. Jiang Wand Newsham IF (2006). Tumor suppressor DAL-1/4.1B and protein methylation cooperate in inducing apoptosis in MCF-7 breast cancer cells. Mol Cancer 15, 4.
40. Liu BH, Yang Y, Paton JF, Li F, Boulaire J, Kasparov S, and Wang S (2006). GAL4-NF-kB fusion protein augments transgene expression from neuronal promoters in the rat brain. Mol Ther 14(6), 872-882.
41. U Ueda K, Kawashima H, Ohtani S, Deng WG, Ravoori M, Bankson J, Gao B, Girard L, Minna JD, Roth JA. et al. (2006). The 3p21.3 tumor suppressor NPRL2 plays an important role in cisplatin-induced resistance in human non-small-cell lung cancer cells. Cancer Res 66(19), 9682-9690.
42. Lu C, Sepulveda CA, Ji L, Rajagopal R, O'Connor S, Jayachandran G, Hicks M, Munden R, Lee J, Templeton N. et al. (2007). Systemic therapy with tumour suppressor FUS1-nanoparticles for stage IV lung cancer. In: Proceedings of the Educational Session at the 98th Annual Meeting of the American Association for Cancer Research, April 14-18, 2007. los Angeles, CA. American Association for Cancer Research, Philadelphia, PA. Abstract LB348.